News | June 16, 2008

GE to Distribute Gamma Medica-Ideas' Pre-Clinical Imaging

June 17, 2008 - Gamma Medica-Ideas and GE Healthcare signed an agreement that GE Healthcare will be the exclusive distributor of Gamma Medica-Ideas' preclinical imaging products effective July 1, 2008, as announced at the 55th annual meeting of the Society of Nuclear Medicine.

Pre-Clinical imaging plays a key role in new pharmaceutical therapeutic development by allowing researchers to visualize the structure, function and response of laboratory animals in vivo.

The agreement complements GE Healthcare's portfolio of pre-clinical products, and grants researchers greater access to GM-I's fully-digital trimodality Positron Emission Tomography (PET); Single Photon Emission Computed Tomography (SPECT) and Computed Tomography (CT) scanners.

"This agreement is an opportunity for customers to gain greater access to our hybrid scanners by leveraging the extensive footprint of GE Healthcare,"? said Bradley Patt, Ph.D., president and CEO of GM-I. "We were first to market a trimodal preclinical scanner, and our all-digital technology provides improved spatial resolution, while enabling researchers to share images easily-bringing digital pathology to the pre-clinical arena."

Gamma Medica-Ideas have installed more than 50 multi-modality systems on four continents since 2002. The company's first-to-market all-digital technologies have made it a leader in pre-clinical imaging systems.

"GE Healthcare is excited to be working with Gamma Medica-Ideas," said Eugene Saragnese, vice president and general manager, molecular imaging and CT, GE Healthcare. "This agreement underscores our deep commitment to the molecular imaging and preclinical markets. Many innovations in clinical imaging get their start in the pre-clinical devices, and we continue to look to that space as a showcase for what's possible for the future of human PET, SPECT and CT imaging."

GE Healthcare already offers dual-modality PET/CT, CZT based SPECT/CT and dedicated in-vivo and specimen preclinical CT scanners. The agreement with GM-I brings scalable and upgradeable tri-modal (PET/SPECT/CT) systems under the GE umbrella.

"Researchers across the globe will reap the benefits of the combined multi-modality pre-clinical portfolio of GE Healthcare and Gamma Medica-Ideas accelerating studies to investigate disease biology and develop new drugs,"? said James Mitchell, general manager, molecular imaging technologies, GE Healthcare. "This agreement makes for a one-stop-shop for pre-clinical imaging devices."

For more information: www.gehealthcare.com

Related Content

A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages
Technology and Radionucleotide Development Will Fuel Mobile Gamma Camera Adoption
News | Nuclear Imaging | September 27, 2018
Advancements in healthcare technology, particularly in the surgery category, have led to an increasing adoption of...
Brain Study of 62,454 Scans Identifies Drives of Brain Aging
News | SPECT Imaging | August 27, 2018
In the largest known brain imaging study, scientists from five institutions evaluated 62,454 brain single photon...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
New ASNC SPECT Imaging Guideline Addresses Advances in Myocardial Perfusion Imaging
News | SPECT Imaging | June 21, 2018
The American Society of Nuclear Cardiology (ASNC) has published an update to its 2010 guidelines for single photon...
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
The Chalk River nuclear reactor license has been renewed, but will be decommissioned by 2028.

The Chalk River nuclear isotope reactor license has been renewed, but will be decommissioned by 2028. The reactor supplies about 50 percent of the world's supply of Tc99m.

Feature | Nuclear Imaging | April 02, 2018 | Dave Fornell
April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear Lab
A Tc99m SPECT cardiac exam showing myocardial perfusion in the heart.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 08, 2018 | Dave Fornell
February 8, 2018 — The U.S.